Author

Xavier Roblin

HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD
HIGH SERUM SUBCUTANEOUS INFLIXIMAB LEVELS ARE ASSOCIATED WITH DEEP REMISSION IN PATIENTS WITH IBD

Xavier Roblin  et al.

WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY
WHICH SECOND-LINE BIOLOGIC AFTER ANTI-TNF FAILURE DURING CROHN'S DISEASE: USTEKINUMAB OR VEDOLIZUMAB, A MULTICENTRE RETROSPECTIVE STUDY

Xavier Roblin  et al.

ACUTE INFUSION REACTIONS UNDER VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF A MULTICENTER RETROSPECTIVE OBSERVATIONAL COHORT STUDY
ACUTE INFUSION REACTIONS UNDER VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE PATIENTS: RESULTS OF A MULTICENTER RETROSPECTIVE OBSERVATIONAL COHORT STUDY

Xavier Roblin  et al.

CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY
CHARACTERISTICS OF FILGOTINIB-TREATED PATIENTS WITH ULCERATIVE COLITIS WHO ACHIEVE SUSTAINED CORTICOSTEROID-FREE REMISSION: POST HOC ANALYSIS OF THE PHASE 2B/3 SELECTION STUDY

Xavier Roblin  et al.

EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY
EFFECTIVENESS AND SAFETY OF RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH CROHN’S DISEASE: A GETAID COHORT STUDY

Xavier Roblin  et al.

TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS
TOFACITINIB OR USTEKINUMAB FOR THIRD-LINE TREATMENT OF REFRACTORY ULCERATIVE COLITIS: A MULTICENTER RETROSPECTIVE PROPENSITY SCORE-MATCHED ANALYSIS

Xavier Roblin  et al.

SERIC HAPTOGLOBIN KINETICS MAY PREDICT CLINICAL OUTCOME IN PATIENTS WITH IBD UNDERGOING BIOLOGICS
SERIC HAPTOGLOBIN KINETICS MAY PREDICT CLINICAL OUTCOME IN PATIENTS WITH IBD UNDERGOING BIOLOGICS

Xavier Roblin  et al.

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY
EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION AND MAINTENANCE THERAPY FOR CROHN’S DISEASE: RESULTS FROM THE PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED DIVERSITY1 STUDY

Xavier Roblin  et al.

SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES
SAFETY OF FILGOTINIB IN CROHN’S DISEASE COMPARED WITH ULCERATIVE COLITIS: DATA FROM THE PHASE 3 DIVERSITY1 AND PHASE 2B/3 SELECTION STUDIES

Xavier Roblin  et al.

EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL
EARLY FECAL CALPROTECTIN LEVELS PREDICT POSTOPERATIVE RECURRENCE OF CROHN’S DISEASE: DATA FROM THE REPREVIO TRIAL

Xavier Roblin  et al.

RISANKIZUMAB LEVELS ARE SIGNIFICANTLY CORRELATED AND PREDICTIVE OF BIOMARKER REMISSION IN CROHN'S DISEASE
RISANKIZUMAB LEVELS ARE SIGNIFICANTLY CORRELATED AND PREDICTIVE OF BIOMARKER REMISSION IN CROHN'S DISEASE

Xavier Roblin  et al.

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA
REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Xavier Roblin  et al.

PROTON PUMP INHIBITORS ARE ASSOCIATED WITH A DISABLING COURSE OF CROHN’S DISEASE
PROTON PUMP INHIBITORS ARE ASSOCIATED WITH A DISABLING COURSE OF CROHN’S DISEASE

Xavier Roblin  et al.

ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB
ANTI-USTEKINUMAB ANTIBODIES USING A DRUG TOLERANT ASSAY IS THE ONLY PREDICTIVE FACTOR OF CLINICAL REMISSION IN INFLAMMATORY BOWEL DISEASE PATIENT UNDER USTEKINUMAB

Xavier Roblin  et al.

SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY
SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY

Xavier Roblin  et al.

IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS
IN FAILURE OF NON-OPTIMIZED ADALIMUMAB (ADA) WITH THERAPEUTIC SERUM LEVELS, A CHANGE IN BIOTHERAPY CLASS IS GREATER THAN AN INTENSIFICATION OF ADA DOSE IN PATIENTS WITH CROHN´S DISEASE AND HEMORRHAGIC RECTOCOLITIS

Xavier Roblin  et al.

CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID
CHANGING THE COURSE OF CROHN’S DISEASE WITH AN EARLY USE OF ADALIMUMAB: THE CURE STUDY FROM THE GETAID

Xavier Roblin  et al.

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY
IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Xavier Roblin  et al.

USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE
USTEKINUMAB IS MORE EFFECTIVE THAN AZATHIOPRINE TO PREVENT ENDOSCOPIC POSTOPERATIVE RECURRENCE IN CROHN´S DISEASE

Xavier Roblin  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Xavier Roblin  et al.

Item 1 - 20 / 23
1
2